Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?Zacks Investment Research • 12/05/24
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial LeaderGlobeNewsWire • 12/04/24
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceGlobeNewsWire • 11/12/24
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A WatchSeeking Alpha • 11/07/24
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsGlobeNewsWire • 11/05/24
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual MeetingGlobeNewsWire • 10/29/24
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?Zacks Investment Research • 09/05/24
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial ResultsGlobeNewsWire • 08/06/24
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/26/24
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40InvestorPlace • 07/24/24
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/09/24